Publications
397
Citations
11,446
Est. group size
~42
Recurring co-author estimate
Active years
33
Publishing since 1994
Lianbo Yu's publication record spans a wide range of cancer-related topics, including tumor immunology, cancer genomics, biomarker development, and cell-based therapies such as CAR-T cells. The output reflects contributions across many collaborative studies rather than a single narrow research focus, touching areas like pancreatic cancer diagnostics, glioma biology, hepatocellular carcinoma models, and microRNA-based biomarkers in breast cancer. This profile suggests involvement as a collaborator or statistical/data contributor across multiple cancer biology and clinical oncology projects.
Publication output was relatively steady (11-24 per year) from 2017-2022, then increased sharply in 2023 and has remained elevated through 2025, suggesting a recent growth in research activity or collaborative output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- The independent association of social isolation and loneliness with cognitive frailty in Chinese older adults: a cross-sectional study
BMC Public Health · 2025
- Development of a comprehensive cfDNA methylation signature for prognostic, predictive, and diagnostic applications in pancreatic ductal adenocarcinoma (PDA).
Journal of Clinical Oncology · 2025
- Transient Receptor Potential Melastatin 4 (TRPM4) is associated with an immuno-stimulatory TME and better prognosis in BLCA
Discover Oncology · 2025
- Analysis Based on TCGA Data and Single-cell Data, taking <em>TRPM4</em> as an Example
Journal of Visualized Experiments · 2025
- 807MO High efficacy and safety of interleukin-6-knockdown CD19-targeted CAR-T cells in relapsed/refractory B-ALL patients
Annals of Oncology · 2024
- A novel goldfish orthotopic xenograft model of hepatocellular carcinoma developed to evaluate antitumor drug efficacy
Fish & Shellfish Immunology · 2024
- Supplementary Figure Legends 1-7 from Extracellular Matrix Protein CCN1 Limits Oncolytic Efficacy in Glioma
2023
- Supplementary Tables 1-2, Figures 1-7 from Extracellular Matrix Protein CCN1 Limits Oncolytic Efficacy in Glioma
2023
- Supplementary Tables 1-2, Figures 1-7 from Extracellular Matrix Protein CCN1 Limits Oncolytic Efficacy in Glioma
2023
- Supplementary Figure Legends 1-7 from Extracellular Matrix Protein CCN1 Limits Oncolytic Efficacy in Glioma
2023
- Data from Reprogramming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis
2023
- Supplementary data and materials from Reprogramming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis
2023
- Supplementary data and materials from Reprogramming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis
2023
- Data from MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions
2023
- Supplemental Tables S1-2, Figures S1-2 from Breast Cancer–Specific miR Signature Unique to Extracellular Vesicles Includes “microRNA-like” tRNA Fragments
2023
- Cancer Research×13
- Journal of Clinical Oncology×7
- Oncotarget×5
- Scientific Reports×5
- Cancer Immunology Research×4
- Karuppaiyah Selvendiran
Medicine · The Ohio State University
- Pui‐Kai Li
Medicine · The Ohio State University
- Fode Tounkara
Medicine · The Ohio State University
- William E. Carson
Immunology and Microbiology · The Ohio State University
- Hazem E. Ghoneim
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile